EU Approves Merck's KEYTRUDA As Adjuvant Therapy For Renal Cell Carcinoma
27/1 14:11
(RTTNews) - The European Commission has approved Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of m...